Chai Discovery
Chai Discovery builds proprietary AI foundation models (Chai-1, Chai-2, Chai-3) for biomolecular structure prediction and de novo antibody and miniprotein design, serving large pharmaceutical companies via multi-year licensing deals with Eli Lilly and Pfizer.
- Company typePrivate
- Founded2024
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Chai Discovery does
Chai Discovery is a private, venture-backed AI biotech founded in 2024 in San Francisco that builds multi-modal generative foundation models to predict and reprogram the interactions between biological molecules. Its core technology stack spans three generations of proprietary models — Chai-1 (multi-modal all-atom structure prediction across proteins, DNA, RNA, small molecules, and covalent modifications, released open-source under Apache 2.0), Chai-2 (zero-shot generative design of antibodies, nanobodies, and miniproteins achieving ~16% antibody binding and ~68% miniprotein wet-lab hit rates), and Chai-3 (next-generation model with doubled antibody-design success rates and multi-specific engineering, delivered via early-access channels). Wet-lab outcomes are independently validated, including Cryo-EM-confirmed sub-angstrom accuracy on full-length monoclonal antibodies designed against challenging GPCR and peptide-MHC targets.
The company monetizes primarily through multi-year strategic licensing agreements with large pharmaceutical companies, including a reported mid-eight-figure annual platform fee from Eli Lilly (signed Jan 2026) and a license with Pfizer (signed Jun 2026) that bundles early Chai-3 access with a custom model trained on the partner's proprietary data. A second tier of revenue comes from commercial subscriptions to Chai-2 via gated access, freemium academic access, and free-trial distribution of its miniprotein design suite to biotechs participating in Eli Lilly's TuneLab program. Go-to-motion is enterprise field sales into pharma R&D leadership; Chai also distributes through the NVIDIA BioNeMo ecosystem.
Chai Discovery firmographics
Firmographics- Name
- Chai Discovery
- Legal name
- Chai Discovery
- Website
- https://chaidiscovery.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Chai Discovery builds proprietary AI foundation models (Chai-1, Chai-2, Chai-3) for biomolecular structure prediction and de novo antibody and miniprotein design, serving large pharmaceutical companies via multi-year licensing deals with Eli Lilly and Pfizer.
- Ownership category
- akta.pro rank
Chai Discovery industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Chai Discovery is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Chai Discovery business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Pharma licensing agreements: Multi-year strategic license agreements with pharmaceutical companies (Eli Lilly, Pfizer) granting access to foundation models and custom-trained models on the partner's proprietary data; upfront licensing value plus milestone economics.
- Recurring annual platform fees: Multi-year, mid-eight-figure annual platform fees paid by large pharma for biologics design access, embedding the model into partner discovery workflows.
- Commercial access subscriptions: Access to Chai-2 for commercial organizations via gated access request, with ongoing commercial relationships supporting research and product development.
- Co-developed custom AI models: Revenue from developing purpose-built AI models trained on a partner's proprietary data, delivered as part of broader strategic collaboration packages (e.g., the bespoke model for Lilly, custom model for Pfizer).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Commercial access to Chai-2 |
| Freemium | Pay-as-you-go | Academic non-commercial access to Chai-2 |
| Other | Multi-year contract | Enterprise pharma platform license |
| Freemium | Pay-as-you-go | Free trial via Lilly TuneLab |
| Freemium | Pay-as-you-go | Chai-1 free open access |
Go-to-market motion1 record
Chai Discovery product offering
Product offeringCore offering
Chai Discovery develops multi-modal generative AI foundation models (Chai-1, Chai-2, Chai-3) that predict and reprogram biochemical molecule interactions. The company designs and engineers novel biologics—including monoclonal antibodies, nanobodies, scFvs, miniproteins, and other biomolecules—by predicting structures and generating de novo binders against specified targets. Its platforms serve pharmaceutical and biotechnology partners for drug discovery and biologics design.
Product overview
Chai Discovery offers a platform of proprietary AI foundation models for molecular design and drug discovery, comprising three generations of models: Chai-1 (multi-modal molecular structure prediction, publicly accessible), Chai-2 (zero-shot de novo antibody and miniprotein design, commercially licensed), and Chai-3 (next-generation model under early access). Chai-1 is distributed to the public via the free Chai Lab Web Interface (lab.chaidiscovery.com) and the open-source chai-lab software library on GitHub under Apache 2.0 license. Chai-2 and its Miniprotein Design Suite are accessed through commercial partnerships (e.g., Eli Lilly, Pfizer, Lilly TuneLab). Together the platform enables scientists to predict, design, and reprogram biomolecular interactions, compressing drug discovery timelines from months or years to weeks.
Differentiator
Problem solved
Functional benefit
Products and services
- Chai-1 Multi-modal foundation model for molecular structure prediction across proteins, small molecules, DNA, RNA, covalent modifications, and ligands. Achieves state-of-the-art accuracy on drug discovery benchmarks and runs single-sequence mode without MSAs while preserving most performance.
- Chai-2 Zero-shot generative platform for fully de novo antibody and miniprotein design, enabling epitope-specific binder generation without high-throughput screening. Achieves double-digit experimental success rates across scFvs, VHH/nanobodies, miniproteins, and full-length mAbs.
- Chai-2 mAb Extension of Chai-2 to full-length, drug-like monoclonal antibody design with developability characteristics on par with well-behaved therapeutic antibodies. Validated via Cryo-EM at sub-angstrom accuracy and demonstrated on challenging GPCR and peptide-MHC targets.
- Chai-3 Next-generation foundation model that doubles Chai-2's success rate in AI-driven antibody design, enables multi-specific molecule engineering, and reduces antibody design failure rates by half compared to Chai-2. Provided via early-access license to Pfizer.
- chai-lab (open-source library) Open-source software library providing Chai-1 model weights and inference code under Apache 2.0 license, enabling programmatic molecular structure prediction for free commercial and academic use.
- Chai Lab Web Interface Free web-based interface for running Chai-1 molecular structure prediction, available for commercial applications including drug discovery.
- Miniprotein Design Suite Chai's miniprotein design suite enabling in-silico molecular candidate generation without traditional library screening. Achieves extremely high success rates (>50%) for miniproteins.
Companies that use Chai Discovery
Customer profileIdeal customer profiles2 records
Chai Discovery technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature5 records
Chai Discovery partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights3 records
Chai Discovery competitors and assessment
Company assessmentDirect peers
- Isomorphic Labs: Alphabet-backed AI drug discovery company building foundation models for molecular structure prediction and drug design. Most direct competitor to Chai-1/2/3, targeting the same large-pharma licensing model.
- Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. Directly comparable AI-native biotech commercializing foundation models to pharma, with broader small-molecule focus but overlapping biologics ambitions.
- Generate Biomedicines: Flagship Pioneering–backed generative biology company building foundation models (Chroma) to program novel protein therapeutics. Closest direct competitor in generative biologics and antibody/miniprotein design.
- Absci: AI-driven generative biology company with an integrated wet lab for antibody design. Chai's co-founders include former Absci employees, and the company competes for the same pharma antibody-discovery budgets.
- Genesis Therapeutics: AI-native drug discovery company building foundation models (DynamicBPNet) for molecular simulation and protein-ligand interaction prediction. Targets the same pharma licensing and co-development model for AI-designed therapeutics.
- Iambic (formerly Entos): AI-driven drug discovery company building physics-based and ML foundation models for small-molecule and protein design. Comparable in stage, capital intensity, and pharma partnership strategy.
Broad incumbents
- Recursion Pharmaceuticals: Publicly listed AI-driven biotech combining high-throughput wet-lab experimentation with foundation models for target identification and small-molecule discovery. Operates at greater scale and broader scope than Chai, with established pharma partnerships.
Emerging players
- Cradle Bio: AI protein design startup focused on engineering novel protein therapeutics and enzymes. Comparable technology stack and target customer base (biologics-focused pharma), with somewhat narrower scope than Chai's full biomolecule platform.
- EvolutionaryScale: AI frontier-model company for biology, founded by former Meta FAIR researchers (overlap with Chai's founding team backgrounds). Competes in the foundation-model-for-biology layer that powers Chai-1/2/3.
- Aqemia: AI-driven drug discovery startup combining deep generative models with physics-inspired approaches for small-molecule discovery. Chai's co-founders include former Aqemia contributors; comparable in stage and AI-native biotech positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Chai Discovery social profiles
Digital presenceChai Discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chai Discovery leadership team
Management profileNumber of profiles
Profiles7 records
Chai Discovery funding detail
Funding detailFunding overview
Funding rounds6 records
Investors28 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chai Discovery M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chai Discovery
What does Chai Discovery do?
Chai Discovery develops multi-modal generative AI foundation models (Chai-1, Chai-2, Chai-3) that predict and reprogram biochemical molecule interactions. The company designs and engineers novel biologics—including monoclonal antibodies, nanobodies, scFvs, miniproteins, and other biomolecules—by predicting structures and generating de novo binders against specified targets. Its platforms serve pharmaceutical and biotechnology partners for drug discovery and biologics design.
Is Chai Discovery a public or private company?
Chai Discovery is a private company. It is classified as venture growth investor backed and is currently operating.
When was Chai Discovery founded?
Chai Discovery was founded in 2024. It employs 11 to 50 people.
Where is Chai Discovery based?
Chai Discovery is headquartered in San Francisco, United States, in the North America region.
How does Chai Discovery make money?
Four revenue lines are on record. Pharma licensing agreements are the primary driver. The others are recurring annual platform fees, commercial access subscriptions and co-developed custom AI models.
Who are Chai Discovery's main competitors?
Direct peers on record are Isomorphic Labs, Insilico Medicine, Generate Biomedicines, Absci, Genesis Therapeutics and Iambic (formerly Entos). Recursion Pharmaceuticals is listed as a broad incumbent. Emerging players are Cradle Bio, EvolutionaryScale and Aqemia.
Does Chai Discovery have an API?
Yes. Chai-1 is publicly distributed as an open-source software library (chai-lab) under Apache 2.0 license, providing model weights and inference code hosted on GitHub at github.com/chaidiscovery/chai-lab, and also as a free web interface at lab.chaidiscovery.com available for commercial applications such as drug discovery. Developers can run molecular structure predictions programmatically using the library. Developer documentation is at github.com/chaidiscovery/chai-lab.
What industry is Chai Discovery in?
Chai Discovery's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.